#USA #Smithfield #ALCOR Scientific #Erythrocyte Sedimentation Rate #C-Reactive Protein

New Economic Insights on Laboratory Testing

Introduction

A new economic analysis highlights the substantial financial benefits of incorporating both Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) tests in hospital settings. Conducted by ALCOR Scientific, this study published in 026 in the journals ClinicoEconomics and Outcomes Research emphasizes that maintaining ESR testing is critical for accurate diagnostics in patients with inflammatory diseases.

The Case for Multiple Testing

The major question posed by the study is whether it is worth the financial investment to continue using ESR alongside CRP, particularly in light of recent pressures to eliminate what some see as redundant tests. Critics of combined testing assert that using both is unnecessary; however, the findings convincingly rebut this perspective.

The study shows that applying both ESR and CRP tests reduces the instances of misdiagnosis, leading to substantial cost savings. At a typical academic medical center with 739 beds, the analysis estimates annual savings of approximately $9.95 million thanks to decreased follow-up costs resulting from inaccurate diagnoses—a scenario predominantly caused by false positives associated with CRP tests.

Biological Differences Matter

Critics have often grouped ESR and CRP tests together as if they serve the same purpose. In reality, they yield complementary results due to their different biological behaviors: CRP levels rise quickly in response to acute inflammation and normalize within a few days, while ESR increases at a slower rate, remaining elevated for a longer period. This unique profile makes ESR particularly valuable in detecting chronic and subacute inflammatory conditions, such as rheumatoid polymyalgia, giant cell arteritis, lupus, and some cancers. Together, these tests enhance diagnostic accuracy in ways that relying solely on one could never replicate.

Why This Research Holds Significance

This research is particularly timely amidst ongoing efforts to optimize healthcare spending. The previous initiative known as 'Choosing Wisely' aimed to pressure healthcare systems into reducing what was deemed 'unnecessary' laboratory testing, often targeting ESR. This initiative emerged when ESR testing was primarily manual, unlike today's fully automated methods. Evidence of the financial impacts on healthcare systems was minimal, further complicating the issue.

With an automated ESR test costing just $2.70—less than a cup of coffee—this test no longer burdens clinical laboratory resources due to automation. The investment to conduct both tests is minimal while the returns in terms of avoided misdiagnoses and unnecessary follow-up evaluations are considerable.

Financial Aspects and Cost-Effectiveness

The current reimbursement rates from Medicare and Medicaid Services for ESR and CRP reflect their affordability, with subsequent care costs stemming from misdiagnoses calculated via clinical guidelines and verified by healthcare professionals. Notably, the economic model used simulated groups of 100 patients, evaluating conditions such as rheumatoid arthritis, inflammatory bowel disease, periprosthetic joint infections, and more.

The analysis remained robust across various scenarios, considering different test costs, follow-up expenses, and diagnostic accuracy data.

Consequentially, findings from this study indicate that reducing ESR testing in an effort to cut costs may inadvertently lead to increased overall healthcare expenses due to the resulting misdiagnoses. Implementing both ESR and CRP tests significantly reduces the likelihood of incorrect diagnoses while curbing the costs associated with necessary follow-ups.

Conclusion

As new, automated ESR analyzers become standard in clinical laboratories, the challenge of justifying their necessity persists. The argument against ESR testing ventures into fragile territory when weighed against the clear diagnostic value it delivers at a minimal cost. This study cuts through the pressures to eliminate ESR by illustrating that when both ESR and CRP are employed, the risk of misdiagnosis decreases significantly, ultimately benefiting hospitals financially and improving patient outcomes.

For more detailed insights, refer to the original study by Yarnoff et al.

Contact Information

For media inquiries, contact Lexa Sullivan at ALCOR Scientific via email at email protected] The complete study is openly accessible [here.